Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) was the target of some unusual options trading activity on Thursday. Stock traders acquired 4,052 call options on the stock. This is an increase of 103% compared to the typical volume of 1,999 call options.
Reviva Pharmaceuticals Stock Down 5.5 %
Shares of NASDAQ RVPH opened at $1.90 on Friday. The business’s 50 day moving average price is $1.48 and its two-hundred day moving average price is $1.27. The company has a market cap of $63.54 million, a PE ratio of -1.71 and a beta of -0.02. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $5.67.
Wall Street Analyst Weigh In
Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its holdings in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Free Report) by 17.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent reporting period. Institutional investors own 63.18% of the company’s stock.
Reviva Pharmaceuticals Company Profile
Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.
Read More
- Five stocks we like better than Reviva Pharmaceuticals
- How to Read Stock Charts for Beginners
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- What is a Special Dividend?
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- What is a buyback in stocks? A comprehensive guide for investors
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.